Back to top
more

Pharming Group (PHAR)

(Delayed Data from NSDQ)

$10.45 USD

10.45
4,437

+0.62 (6.31%)

Updated Apr 25, 2024 03:55 PM ET

After-Market: $10.96 +0.51 (4.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PHAR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Pharming Group N.V. Sponsored ADR [PHAR]

Reports for Purchase

Showing records 1 - 20 ( 35 total )

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

03/14/2024

Company Report

Pages: 8

2023 Results; Revenues, Shopping, and Solid Foundations, Oh My; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

01/08/2024

Daily Note

Pages: 4

Ruconest Outperforms and Joenja Continues Strong Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

12/13/2023

Company Report

Pages: 6

Leniolisib Plots New Course to Expand Therapeutic Reach Into PIDs; Phase 2 Start Planned for 2Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

11/21/2023

Daily Note

Pages: 4

First Patient Dosed in Second Pediatric Phase 3 Trial of Leniolisib in APDS; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

11/10/2023

Daily Note

Pages: 4

Leniolisib''s Global Footprint Begins to Grow; European MAA Decision Could Come as Early as 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

10/26/2023

Company Report

Pages: 9

Product Revenues Beat; Looking For New Joenja Territories and Indications; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

08/09/2023

Daily Note

Pages: 8

Leniolisib Sets Foot in Asia; Phase 3 APDS Trial Up and Enrolling in Japan

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

08/03/2023

Company Report

Pages: 8

2Q23 Results; Strong Joenja Launch; Focus On Expanding to Key Global Markets

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

05/11/2023

Company Report

Pages: 8

1Q23 Results; Joenja Commercial Launch Starts Off Strong; European Regulatory Decision Expected 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

03/27/2023

Company Report

Pages: 8

Bringing Balance to the Force; Joenja Approved as First APDS Rx; PRV Cash Could be Inbound

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

03/16/2023

Company Report

Pages: 7

2022 Results; Leniolisib Approaches Finish Line; PDUFA Date March 29, 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

02/21/2023

Daily Note

Pages: 6

First Patient Enrolled in First Pediatric APDS Trial of Leniolisib; PDUFA Date for Adults and Adolescents March 29

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

02/16/2023

Company Report

Pages: 8

EMA Downshifts Leniolisib''s Review; PDUFA Date Remains on Track for March 29, 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

12/15/2022

Company Report

Pages: 8

OLE Study Supports Positive Phase 2/3 Data of Leniolisib in APDS; March 29, 2023 PDUFA ; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

10/28/2022

Daily Note

Pages: 5

Another Regulatory Feather in the Cap; Accelerated Assessment For Leniolisib; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

10/27/2022

Company Report

Pages: 7

3Q22 Results; Busy Times With Core Ruconest Growth and Leniolisib PDUFA March 29, 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

10/11/2022

Daily Note

Pages: 4

Leniolisib Clears Important Next Step Towards Approval in EEA; MAA Submitted, Authorization Anticipated 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

09/28/2022

Daily Note

Pages: 4

Priority Review For Leniolisib; Moving Toward Commercialization Backed by Robust Phase 2/3 Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

08/04/2022

Company Report

Pages: 6

2Q22 Results; With Continued Ruconest Revenue Stream, Focus Now Is On Launch Preparation For Leniolisib

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pharming Group N.V. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

08/01/2022

Daily Note

Pages: 4

Leniolisib Garners EMA Accelerated Assessment; MAA Filing By Year End

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party